MMP9 and ischemia: During the last 20 years, MMP-9 has been identified as aberrantly overactive in ischemia, potentially causing deleterious effects during ischemia and after RE; therefore its inhibition has been suggested as a potential therapeutic target (Dong et al., 2009).